Speed of access to medical innovations is critical to ensuring patients benefit from new treatments.
The EU can play a key role in supporting Europe to become a leader in R&D and driving faster access decisions through enhanced cooperation on Health Technology Assessment (HTA).
We also look to the EU to support and protect Intellectual Property (IP), as this is the lifeblood of our industry and the foundation of medical discoveries. Investment into high-risk areas such as Alzheimer's depends on the certainty of strong and predictable IP incentives and rewards.
Here we give our views on policies that can help bolster IP-intensive industries like our own to speed up the development of better and safer medicines for patients.